



Supplementary Figure 18. Second round of screening of newly developed monoclonal antibody and dimeric nanobody reagent pairs in patient plasma. Affinity reagent pairs selected from a first round of screening in plasma samples (Supplementary Figure 9) were screened in 25 healthy and 25 cancer (colorectal, gastroesophageal, and breast) patient plasma samples. Each assay is denoted by the capture/detector reagent pair. The first-generation assay (Nb5/Ab6) measurements are depicted for comparison (gray box). Blue dashed lines indicate assay limits of detection, accounting for four-fold dilution. Blue boxes indicate the final three selected second-generation assays.